RS
NTLA icon

R Squared’s Intellia Therapeutics NTLA Stock Holding History

R Squared’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Buy
+15,246
New +$213K 0.14% 274
2025
Q4 		– Sell
-10,782
Closed -$186K – 656
2025
Q3 		$186K Buy
+10,782
New +$133K 0.08% 396
2025
Q1 		– Sell
-1,630
Closed -$19K – 1082
2024
Q4 		$19K Buy
+1,630
New +$25.4K 0.02% 901

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

R Squared's NTLA Position: Q2 2026 in Review

R Squared opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 15,246 shares worth $258K. The stake represents 0.14% of the portfolio and ranks #274 among its holdings. This is a return to the name: R Squared previously reported a position in NTLA as recently as Q3 2025.

R Squared first reported a position in NTLA in Q4 2024 and has held it in 3 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • R Squared held 15,246 shares of Intellia Therapeutics worth $258K as of Q2 2026.
  • Intellia Therapeutics was a new R Squared position in Q2 2026.
  • Intellia Therapeutics made up 0.14% of R Squared's portfolio in Q2 2026, its #274 holding.
  • R Squared first reported a position in Intellia Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.